European VCs may be better prepared for a downturn than their US peers Posted on 11.07.202218.07.2022 by Oliver Kahl
BioNTechs second act: can it transform the fight against cancer? Posted on 15.06.202230.06.2022 by Oliver Kahl
BioNTech and beyond: under the skin of one of Europe´s leading biotech investors. Posted on 27.06.202227.06.2022 by Oliver Kahl
